Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2021-04-30
Chief Tech/Sci/R&D Officer 65 2019-03-31
Corporate Officer/Principal - 2012-12-31
Director TitleAgeSince
Director/Board Member 77 1999-07-07
Director/Board Member 54 2021-05-19
Chairman 67 2023-05-28
Date Insider Type Main position Quantity % Market Cap.
23-01-09Sell

Director

8,500 0.0152%
22-09-18Buy

Chief Executive Officer

82,372 0.1562%
22-09-16Buy

Chief Executive Officer

82,372 0.1562%
Change 5-day change 1-year change 3-year change Capi.($)
-2.23%-3.20% - - 13.55M
+4.73%+3.38%+19.53%-8.89% 66.56B
-1.93%+0.39%+58.62%+226.33% 56.51B
+1.07%+42.10%+42.10%+42.10% 42.98B
+3.45%+6.04%-49.46%-55.91% 40.46B
+3.04%+0.04%+62.66%-24.29% 31.91B
+10.01%+18.57%+161.59%-34.48% 31.65B
+2.68%+2.73%+70.72%+88.24% 23.35B
+2.87%+16.83%+3.78%+192.67% 19.46B
-0.13%+2.75%+67.48%+130.07% 17.18B
Average +2.36%+8.76%+48.56%+61.76% 36.67B
Weighted average by Cap. +2.79%+7.31%+43.69%+54.30%
Logo Mithra Pharmaceuticals S.A.
Mithra Pharmaceuticals SA is a Belgian biopharmaceutical company dedicated to transforming women's health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra Pharmaceuticals S.A. explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrolbased product in 2021, the contraceptive pill ESTELLE®, Mithra is now focusing on its second product DONESTA®, the next-generation hormone therapy. Mithra Pharmaceuticals S.A. also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO.
Employees
270